PubMed Health⌕ Search

Biomedical subjects

Y Yahara

Publications and source records attributed to Y Yahara.

15 recordsLinked to original sources
PubMed1989

Simultaneous production of IgG lambda and IgA lambda in a clone of myeloma cells.

We describe a patient (KY) with multiple myeloma and double paraproteinemia. The patient's serum contained IgG lambda and IgA lambda myeloma proteins. An anti-idiotypic antiserum to purified KY IgA was prepared in rabbits, and it was found that KY IgA and KY IgG shared common antigenic determinants, which appeared to be located in variable regions of both the heavy and light chains. Double staining experiments using an anti-alpha chain antibody conjugated with fluorescein isothiocyanate and anti-gamma chain antibody conjugated with rhodamine showed that virtually all plasma cells were stained for both antibodies simultaneously.

Aged↗
PubMed1989

[Chronic myelocytic leukemia following chemotherapy of acute promyelocytic leukemia].

Ph1-positive chronic myelocytic leukemia (CML) developing in a treated case of acute promyelocytic leukemia (APL) is reported. The patient was a 62-year-old male who was diagnosed as having APL in December 1978. He was treated with daunorubicin, Ara-C and 6MP and a complete remission was obtained 4 months later. But APL recurred in February 1981. He was treated with BHAC, aclarubicin, 6MP and prednisolone. He remained in continuous complete remission for 5 years, when all therapy was discontinued. After then, the leukocytes count continued to rise and a diagnosis of Ph1-positive CML was made in September 1986. His leukocytes count has been well controlled with the use of busulfan. The event in this case suggests a possibility of the Ph1-positive CML being a secondary disease related to prior long term chemotherapy.

Aclarubicin↗
PubMed1983

Activation of platelets in cancer, especially with reference to genesis of disseminated intravascular coagulation.

Seventy-five cancer patients were evaluated on a scale of coagulation abnormalities related to DIC, one point given for each of the following criteria fulfilled and the score (0 to 4) being used. 1. Platelet count less than 150 x 10(3)/mu 1. 2. PT prolonged more than 1 sec over control or APTT prolonged more than 10 sec over control. 3. Fibrinogen less than 250 mg/dl (mean fibrinogen value of the cancer patients minus 1SD). 4. FDP greater than or equal to 20 micrograms/ml. The patients were distributed with 27% for score 0, 38% for 1, 20% for 2, 7% for 3 and 8% for 4. Platelet mode volume in score 4 was smaller than that of the other groups. Platelet aggregation by epinephrine was decreased in score 3 and 4 (P less than 0.01), while it was increased in score 0 (P less than 0.05). ADP-induced aggregation was increased in score 0 and 1 (P less than 0.01 - 0.05). The mean value of beta-thromboglobulin in cancer patients (44 +/- 24 ng/ml) was significantly higher than that of control (22 +/- 13 ng/ml) (P less than 0.01). These results suggest the existence of hyperfunction of platelets in cancer patients and possibility of a triggering mechanism of such activated platelets in the genesis of DIC in cancer.

Adult↗